Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EIF4A3 | P38919 | 8/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699622 | 0.85 | HPGD (0.45) | MDM2LMNAPOLBEIF4A3HSP90AA1 | |
| SCHEMBL13699635 | 0.82 | MEN1 (0.41) | MDM2EIF4A3KMT2A | |
| SCHEMBL13699633 | 0.80 | AKR1C3 (0.48) | MDM2LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL13699645 | 0.80 | MEN1 (0.43) | MDM2LMNAPOLBKMT2AALDH1A1 | |
| SCHEMBL13699651 | 0.78 | MDM2 (0.41) | MDM2EIF4A3 | |
| SCHEMBL13699641 | 0.78 | AKR1C3 (0.50) | MDM2LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL11957724 | 0.76 | ALDH1A1 (0.59) | MDM2LMNAEIF4A3KMT2AALDH1A1 | |
| SCHEMBL13699644 | 0.76 | AKR1C3 (0.49) | LMNAPOLBHPGDAKR1C3 | |
| SCHEMBL13699638 | 0.75 | SMN1; SMN2 (0.49) | LMNAKMT2AALDH1A1 | |
| SCHEMBL11958707 | 0.74 | LMNA (0.54) | MDM2LMNAEIF4A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885LMNA 1997/4885POLB 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.